iCAD (ICAD) Upgraded to “Sell” at ValuEngine
ValuEngine upgraded shares of iCAD (NASDAQ:ICAD) from a strong sell rating to a sell rating in a research report sent to investors on Thursday morning.
Shares of iCAD (NASDAQ ICAD) traded down $0.12 during trading hours on Thursday, hitting $3.88. 66,500 shares of the stock were exchanged, compared to its average volume of 62,425. The stock has a market capitalization of $63.79, a price-to-earnings ratio of -4.73 and a beta of 1.54. iCAD has a fifty-two week low of $3.13 and a fifty-two week high of $6.07. The company has a current ratio of 1.95, a quick ratio of 1.67 and a debt-to-equity ratio of 0.31.
iCAD (NASDAQ:ICAD) last issued its quarterly earnings data on Wednesday, November 8th. The technology company reported ($0.13) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.01. The company had revenue of $7.00 million for the quarter, compared to analyst estimates of $7.43 million. iCAD had a negative net margin of 49.16% and a negative return on equity of 47.31%. sell-side analysts expect that iCAD will post -0.62 EPS for the current fiscal year.
A number of hedge funds have recently modified their holdings of the stock. Argent Capital Management LLC increased its holdings in iCAD by 13.2% during the second quarter. Argent Capital Management LLC now owns 713,650 shares of the technology company’s stock valued at $2,990,000 after buying an additional 82,967 shares during the period. Vanguard Group Inc. increased its holdings in iCAD by 0.4% during the second quarter. Vanguard Group Inc. now owns 456,377 shares of the technology company’s stock valued at $1,912,000 after buying an additional 2,007 shares during the period. Dimensional Fund Advisors LP increased its holdings in iCAD by 165.1% during the third quarter. Dimensional Fund Advisors LP now owns 89,043 shares of the technology company’s stock valued at $394,000 after buying an additional 55,455 shares during the period. Finally, Segall Bryant & Hamill LLC purchased a new position in iCAD during the third quarter valued at approximately $133,000. 21.98% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “iCAD (ICAD) Upgraded to “Sell” at ValuEngine” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://www.watchlistnews.com/icad-icad-upgraded-to-sell-at-valuengine/1798672.html.
iCAD Company Profile
iCAD, Inc is a provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The Company provides image analysis and clinical decision support solutions for mammography, Magnetic Resonance Imaging and Computed Tomography imaging. It operates in two segments: Cancer Detection (Detection) and Cancer Therapy (Therapy).
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with Analyst Ratings Network's FREE daily email newsletter.